Abstract
LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have